Harrow (HROW) Stock Price, News & Analysis

Company Overview

Harrow Health, Inc. (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives. Its product portfolio includes preservative-free and compounded prescription eye drop formulations, which are distributed nationwide across all 50 states. The company leverages a targeted commercial infrastructure to support independent ophthalmologists, optometrists and surgical centers, while maintaining a research pipeline aimed at novel delivery technologies and formulations.

Originally operating under the name ImprimisRx, the company officially adopted the Harrow Health name in mid-2021 to reflect its broader strategic focus on eye health. Harrow Health is led by Chairman and Chief Executive Officer Robert A. Ward, whose leadership, together with an experienced management team, has driven both commercial expansion and product innovation in the ophthalmology space.

Key Stats

• Today's Range: $35.62 to $37.11
• 50-Day Range: $30.54 to $40.01
• 52-Week Range: $20.85 to $59.23
• Volume: 235,738 shs
• Average Volume: 479,128 shs
• Market Capitalization: $1.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $64.67
• Consensus Rating: Buy

Harrow Stock Analysis - MarketRank™

Harrow scored higher than 72% of companies evaluated by MarketBeat, and ranked 298th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Harrow has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Harrow has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Harrow are expected to grow in the coming year, from ($0.53) to $0.40 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Harrow is -147.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harrow is -147.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harrow has a P/B Ratio of 18.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.03% of the outstanding shares of Harrow have been sold short.

Short Interest Ratio / Days to Cover

Harrow has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Harrow has recently increased by 7.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harrow does not currently pay a dividend.

Dividend Growth

Harrow does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.03% of the outstanding shares of Harrow have been sold short.

Short Interest Ratio / Days to Cover

Harrow has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Harrow has recently increased by 7.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.38

News Sentiment

Harrow has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Harrow this week, compared to 6 articles on an average week.

Search Interest

10 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

11 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harrow insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.16% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HROW Stock Analysis - Frequently Asked Questions

How have HROW shares performed this year?

Harrow's stock was trading at $33.55 at the start of the year. Since then, HROW stock has increased by 10.1% and is now trading at $36.9410.

How were Harrow's earnings last quarter?

Harrow, Inc. (NASDAQ:HROW) issued its quarterly earnings results on Monday, August, 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. The company had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative net margin of 4.49% and a negative trailing twelve-month return on equity of 2.18%.
Read the conference call transcript.

Who are Harrow's major shareholders?

Harrow's top institutional shareholders include Opaleye Management Inc. (10.55%), Braidwell LP (2.36%), Geode Capital Management LLC (2.21%) and Marshall Wace LLP (1.54%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Martin A Makary, Richard L Md Lindstrom and Horn R Lawrence Van.
View institutional ownership trends.

How do I buy shares of Harrow?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Harrow own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/05/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HROW
• Previous Symbol: NASDAQ:HROW
• CIK: 1360214
• Web: www.harrowinc.com
• Phone: (615) 733-4730
• Fax: 858-345-1745
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Harrow: $64.67
• High Price Target: $76.00
• Low Price Target: $55.00
• Potential Upside/Downside: +76.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.48 million
• Net Margins: -4.49%
• Pretax Margin: -4.71%
• Return on Equity: -2.18%
• Return on Assets: -0.35%

Debt

• Debt-to-Equity Ratio: 0.78
• Current Ratio: 0.62
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: $199.61 million
• Price / Sales: 6.79
• Cash Flow: $0.13 per share
• Price / Cash Flow: 273.07
• Book Value: $1.95 per share
• Price / Book: 18.78

Miscellaneous

• Outstanding Shares: 37,000,000
• Free Float: 31,392,000
• Market Cap: $1.35 billion
• Optionable: Optionable
• Beta: 0.33